Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Retained Earnings (2016 - 2026)

Viking Therapeutics (VKTX) has disclosed Retained Earnings for 13 consecutive years, with -$1.0 billion as the latest value for Q1 2026.

  • For Q1 2026, Retained Earnings fell 88.53% year-over-year to -$1.0 billion; the TTM value through Mar 2026 reached -$1.0 billion, down 88.53%, while the annual FY2025 figure was -$847.5 million, 73.71% down from the prior year.
  • Retained Earnings hit -$1.0 billion in Q1 2026 for Viking Therapeutics, down from -$847.5 million in the prior quarter.
  • Across five years, Retained Earnings topped out at -$239.3 million in Q1 2022 and bottomed at -$1.0 billion in Q1 2026.
  • Average Retained Earnings over 5 years is -$463.7 million, with a median of -$405.3 million recorded in 2024.
  • Year-over-year, Retained Earnings dropped 28.06% in 2024 and then crashed 88.53% in 2026.
  • Viking Therapeutics' Retained Earnings stood at -$292.0 million in 2022, then dropped by 29.41% to -$377.9 million in 2023, then fell by 29.1% to -$487.9 million in 2024, then plummeted by 73.71% to -$847.5 million in 2025, then dropped by 18.68% to -$1.0 billion in 2026.
  • According to Business Quant data, Retained Earnings over the past three periods came in at -$1.0 billion, -$847.5 million, and -$689.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.